Clinical Research Directory
Browse clinical research sites, groups, and studies.
Xenon MRI and Progressive ILD
Sponsor: Duke University
Summary
The XENON ILD study is a single arm, un-blinded study at Duke University enrolling patients with non-idiopathic pulmonary fibrosis (IPF) progressive fibrosis (PF) interstitial lung disease (ILD). Patients who meet criteria for ILD-progression (defined below in inclusion/exclusion criteria) will be consented prior to the initiation of anti-fibrotic therapy. Subjects will undergo an approximately hour long comprehensive MRI protocol, including administration of multiple doses of hyperpolarized 129Xe. The subjects will have this initial study prior to initiation of anti-fibrotic therapies and repeat MRI studies at 3, 6 and 12 months following the initiation of therapy. If subjects do not decide to initiate anti-fibrotic therapy per discussion with their physician, then the 3, 6 and 12 months repeat studies will initiate based on time after enrollment.
Official title: XENON ILD: 129Xe MRI to Evaluate aNtifibrotic respOnse and progressioN in ILD
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2022-07-19
Completion Date
2026-08-31
Last Updated
2026-02-24
Healthy Volunteers
No
Interventions
Hyperpolarized 129 Xenon Gas Comparing Progressive Pulmonary Fibrosis Treatment
Whether magnetic resonance imaging (MRI) using inhaled hyper-polarized 129 Xenon gas can help visualize impaired lung function to detect changes over time in Progressive Pulmonary Fibrosis
Locations (1)
Duke University
Durham, North Carolina, United States